【24h】

Non-melanoma skin cancer

机译:非黑色素瘤皮肤癌

获取原文
获取原文并翻译 | 示例
           

摘要

Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common. Surgery has traditionally been regarded as the 'gold-standard' treatment, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (radiotherapy, curettage and cautery, and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.
机译:非黑色素瘤皮肤癌(NMSC)包括基底细胞癌(BCC)和鳞状细胞癌,以及许多罕见肿瘤。 NMSC是高加索人中最常见的恶性肿瘤,其发病率逐年上升。暴露于紫外线辐射会引发大约90%的NMSC,导致角质形成细胞发生恶性转化并抑制炎症反应。危险因素包括日晒和免疫抑制。 BCC有几种亚型,尽管组织学重叠是常见的。传统上,外科手术被视为“黄金标准”疗法,可提供出色的治愈率和美容效果。其他治疗方式包括物理破坏(放射疗法,刮除术和烧灼术以及冷冻疗法),化学破坏(光动力疗法和局部5-氟尿嘧啶)和免疫调节疗法(局部咪喹莫特)。用于高风险BCC的新型刺猬途径抑制剂(包括口服vismodegib和sonidegib)的最新开发可能代表了向NMSC的医学管理模式的转变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号